Literature DB >> 18082989

Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.

Gerwin P Schmidt1, Andrea Baur-Melnyk, Alexander Haug, Volker Heinemann, Ingo Bauerfeind, Maximilian F Reiser, Stefan O Schoenberg.   

Abstract

PURPOSE: To compare the diagnostic accuracy for the detection of tumor recurrence in breast cancer patients using whole-body-MRI (WB-MRI) at 1.5 or 3T compared to FDG-PET-CT.
MATERIALS AND METHODS: Thirty-three female patients with breast cancer and suspicion of recurrence underwent FDG-PET-CT and WB-MRI. Coronal T1w-TSE- and STIR-sequences, HASTE-imaging of the lungs, contrast-enhanced T1w- and T2w-TSE-sequences of the liver, brain and abdomen were performed, using a WB-MRI-scanner at 1.5 (n=23) or 3T (n=10). Presence of local recurrence, lymph node involvement and distant metastatic disease was assessed using clinical and radiological follow-up as a standard of reference.
RESULTS: Tumor recurrence was found in 20 of 33 patients. Overall 186 malignant foci were detected with WB-MRI and PET-CT. Both modalities revealed two recurrent tumors of the breast. PET-CT detected more lymph node metastases (n=21) than WB-MRI (n=16). WB-MRI was more precise in the detection of distant metastases (n=154 versus n=147). Sensitivity was 93% (172/186) and 91% (170/186) for WB-MRI and PET-CT, specificity was 86% (66/77) and 90% (69/77), respectively. Examination times for WB-MRI at 1.5 and 3T were 51 and 43 min, respectively, examination time for PET-CT was 103 min.
CONCLUSION: WB-MRI and PET-CT are useful for the detection of tumor recurrence in the follow-up of breast cancer. WB-MRI is highly sensitive to distant metastatic disease. PET-CT is more sensitive in detecting lymph node involvement. Tumor screening with WB-MRI is feasible at 1.5 and 3T, scan time is further reduced at 3T with identical resolution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18082989     DOI: 10.1016/j.ejrad.2007.10.021

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  28 in total

Review 1.  The uses and limitations of whole-body magnetic resonance imaging.

Authors:  Gerwin Schmidt; Dietmar Dinter; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Dtsch Arztebl Int       Date:  2010-06-04       Impact factor: 5.594

Review 2.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

Review 3.  Combined PET/MRI: a new dimension in whole-body oncology imaging?

Authors:  Gerald Antoch; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

4.  Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Authors:  Michael A Jacobs; Katarzyna J Macura; Atif Zaheer; Emmanuel S Antonarakis; Vered Stearns; Antonio C Wolff; Thorsten Feiweier; Ihab R Kamel; Richard L Wahl; Li Pan
Journal:  Acad Radiol       Date:  2018-04-04       Impact factor: 3.173

Review 5.  PET-MRI synergy in molecular, functional and anatomical cancer imaging.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

6.  The role of MRI in musculoskeletal practice: a clinical perspective.

Authors:  Gail Dean Deyle
Journal:  J Man Manip Ther       Date:  2011-08

7.  Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.

Authors:  Diomidis Botsikas; Anastasia Kalovidouri; Minerva Becker; Michele Copercini; Dahila Amal Djema; Alexandre Bodmer; Sindy Monnier; Christoph D Becker; Xavier Montet; Benedicte M A Delattre; Osman Ratib; Valentina Garibotto; Claire Tabouret-Viaud
Journal:  Eur Radiol       Date:  2015-10-17       Impact factor: 5.315

Review 8.  The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer.

Authors:  Koosha Paydary; Siavash Mehdizadeh Seraj; Mahdi Zirakchian Zadeh; Sahra Emamzadehfard; Sara Pourhassan Shamchi; Saeid Gholami; Thomas J Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

9.  FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis.

Authors:  LingLing Pan; Yuan Han; XiaoGuang Sun; JianJun Liu; Huang Gang
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-21       Impact factor: 4.553

10.  Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy.

Authors:  Lori R Arlinghaus; Xia Li; Mia Levy; David Smith; E Brian Welch; John C Gore; Thomas E Yankeelov
Journal:  J Oncol       Date:  2010-09-29       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.